RESUMEN
Resumen: La infección por el nuevo SARS-COV-2 ha impactado de diversas maneras a toda la sociedad, incluidos los niños. Se describe el comportamiento de esta enfermedad en una población pediátrica de escasos recursos localizada por encima de 2500 m. s. n. m. Este es un trabajo retrospectivo transversal entre marzo y octubre de 2020 en Bogotá involucró niños entre 1 mes y 14 años con RT-PCR positiva para SARS-COV-2. Se estudiaron antecedentes, características sociodemográficas, clínicas, de laboratorio, radiológicas y evolutivas, agrupando los pacientes según la gravedad y analizando su significancia (p < 0.05). Como resultado, se obtuvieron 416 casos, de los cuales 43.3 % eran asintomáticos, 46.6 % sintomáticos leves, 8.9 % graves y 1.2 % críticos. De los consultantes a urgencias, los menores de 1 año fueron los más frecuentes (56.79 %) y los que más se hospitalizaron (35.8 %). El tiempo entre el inicio de los síntomas y la consulta fue en promedio de 2 días, El diagnóstico más frecuente en los pacientes no hospitalizados fue rinofaringitis (58.97 %), y en los que se hospitalizaron fue bronquiolitis (50 %). La mediana del tiempo de hospitalización de todo el grupo fue de 4 días la cual ser prolongó a 7 días para los que requirieron UCI. Con la hospitalización se asocia, entre otras causas, los índices nutricionales < 2 de, taquipnea, dificultad respiratoria, hipoxemia, linfopenia (en mayores de 2 años) (p < 0.05), no influyendo el hacinamiento ni el nivel socioeconómico. Después del estudio, se pudo concluir que la enfermedad es, generalmente, mucho más leve en niños que en adultos, diferenciándose de estos tanto en los factores predisponentes, los paraclínicos y en la evolución. Sin embargo, algunas variables demográficas, clínicas y de laboratorio podrían asociarse con una mayor gravedad en este grupo poblacional.
Abstract: Infection with the new SARS-COV-2 has impacted the entire society, including children, in various ways. The behavior of this disease in a low-income pediatric population located above 2500 m. a. s. I. is described. This is a cross-sectional retrospective study carried out between March and October 2020 in Bogotá involving children between 1 month and 14years old with positive RT-PCR for SARS-COV-2. History, sociodemographic, clinical, laboratory, radiological and evolutionary characteristics were studied, grouping the patients according to severity and analyzing their significance (p < 0.05). As a result, 416 cases were obtained, of which 43.3 % were asymptomatic, 46.6 % mildly symptomatic, 8.9 % severe, and 1.2 % critical. Of the consultants to the emergency room, those under 1 year of age were the most frequent (56.79 %) and those who were hospitalized the most (35.8 %). The time between the onset of symptoms and consultation was an average of 2 days. The most frequent diagnosis in non-hospitalized patients was rhinopharyngitis (58.97 %), and in those who were hospitalized it was bronchiolitis (50 %). The median hospitalization time for the entire group was 4 days, which was extended to 7 days for those who required ICU. Hospitalization is associated with, among other causes, nutritional indices < 2 SD, tachypnea, respiratory distress, hypoxemia, lymphopenia (in those older than 2 years) (p < 0.05), with neither overcrowding nor socioeconomic status as influencing factors. After the study, it was possible to conclude that the disease is generally much milder among children than in adults, differing from these in predisposing factors, paraclinical factors, and evolution. However, some demographic, clinical and laboratory variables could be associated with greater severity in this population group.
Resumo: A infecção com o novo SARS-COV-2 impactou toda a sociedade de várias maneiras, incluindo crianças. O comportamento desta doença em urna população pediátrica de baixa renda localizada acima de 2.500 m. s. n. m. é descrito. Este é um estudo transversal retrospectivo entre margo e outubro de 2020 em Bogotá, envolvendo crianças entre 1 mês e 14 anos com RT-PCR positiva para SARS- COV-2. Foram estudados antecedentes, características sociodemográficas, clínicas, laboratoriais, radiológicas e evolutivas, agrupando os pacientes de acordo com a gravidade e analisando sua significância (p < 0.05). Como resultado, foram obtidos 416 casos, sendo 43.3 % assintomáticos, 46.6 % sintomáticos leves, 8.9 % graves e 1.2 % críticos. Dos pacientes em pronto-socorro, os menores de 1 ano foram os mais frequentes (56.79 %) e os que mais internaram (35.8 %). O tempo entre o inicio dos sintomas e a consulta foi em média de 2 dias, sendo o diagnóstico mais frequente nos pacientes não internados a rinofaringite (58.97 %), e nos internados foi a bronquiolite (50 %). A mediana do tempo de internação para todo o grupo foi de 4 dias, que foi estendida para 7 dias para aqueles que necessitaram de UTI. A hospitalização está associada, entre outras causas, a índices nutricionais < 2 DP, taquipneia, desconforto respiratório, hipoxemia, linfopenia (nos maiores de 2 anos) (p < 0.05), não influenciando a superlotação ou o nível socioeconómico. Após o estudo, foi possível concluir que a doença geralmente é muito mais branda em crianças do que em adultos, diferindo destes em fatores predisponentes, fatores para clínicos e evolução. No entanto, algumas variáveis demográficas, clínicas e laboratoriais podem estar associadas á maior gravidade nesse grupo populacional.
RESUMEN
BACKGROUND: Beta-blockers (BBs) remain underused in elderly patients with reduced ejection fraction (REF). Our aim was to determine the prognostic impact of different doses of BB in this setting. METHODS AND RESULTS: A single-center observational study was conducted. Inclusion criteria were age≥75 and EF≤0.35. Six months after diagnosis, patients were divided into 3 groups depending on BB dose: no BB (NBB), low dose (<50% of the target dose) (LD), and high dose (≥50%) (HD). Two different analytical approaches were employed: multivariate Cox model and propensity-score (PS) matching. Outcomes were all-cause death and heart failure (HF) admission. We included 559 patients (134 NBB, 259 LD, and 166 HD) with median follow-up of 29.9months. There were 212 deaths (NBB: 70 (52.2%); LD: 94 (36.3%); and HD: 48 (28.9%)) and 171 HF admissions (NBB: 42 (31.3%); LD: 85 (32.8%); and HD: 44 (26.5%)). On multivariate analysis, both LD and HD were associated with improved survival, with no differences between them (HD vs. NBB=0.67, 95% CI=[0.46-0.98], p=0.037; HD vs. LD=1.03, 95% CI=[0.72-1.46], p=0.894; and LD vs. NBB=0.65, 95% CI=[0.48-0.90], p=0.009). However, BB therapy failed to show benefits in HF admissions (p=NS, for each comparison). PS-matched analysis included 198 patients, with similar results to those mentioned above. CONCLUSIONS: BB therapy was associated with a significant reduction in mortality among elderly patients with REF, regardless of dose. Nevertheless, it was not associated with a decrease in HF admissions. Further studies are needed to determine the optimal BB dose in these patients.
